First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

cafead

Administrator
Staff member
  • cafead   Aug 22, 2024 at 11:33: AM
via ImmPACT Bio has received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis (MS) patients.

article source